Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

In vivo imatinib sensitivity in a patient with GI stromal tumor bearing a PDGFRA deletion DIM842-844.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology - 10 Mar 2015

Fanta Paul T, Sicklick Jason K, Betz Bryan L, Peterson Michael R

Abstract excerpt

No abstract is available from the source.

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Benzamides
Share to Gastrointestinal Stromal Tumors
Share to Imatinib Mesylate
Share to Necrosis

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Piperazines

Share to Pyrimidines

Share to Receptor, Platelet-Derived Growth Factor alpha

Share to Tomography, X-Ray Computed

Source

Open in PubMed Open full text

Identifiers

PMID: 24638008
DOI: 10.1200/JCO.2013.50.0082
PMCID: PMC4884274

Genes

PDGFRA

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

In vivo imatinib sensitivity in a patient with GI stromal tumor bearing a PDGFRA deletion DIM842-844.PMID 24638008Read ↗

Low Dose Sorafenib in Gastric Gastrointestinal Stromal Tumour with PDGFRA p.1843-D846 Deletion in an 88-Year-Old Male.Semantic proximity Read ↗

Crenolanib inhibits the drug-resistant PDGFRA D842V mutation associated with imatinib-resistant gastrointestinal stromal tumors.Semantic proximity Read ↗

Oncogene mutational analysis in imatinib naive population of gastrointestinal stromal tumor patients.Semantic proximity Read ↗

Discovery and pharmacological characterization of AZD3229, a potent KIT/PDGFRα inhibitor for treatment of gastrointestinal stromal tumors.Semantic proximity Read ↗

Predicting Clinical Sensitivities of PDGFRA Exon 18 Mutations to Imatinib and Avapritinib to Optimize Gastrointestinal Stromal Tumor Treatment.Semantic proximity Read ↗

Systemic therapy for advanced gastrointestinal stromal tumors: beyond imatinib.Semantic proximity Read ↗

Promising novel therapeutic approaches in the management of gastrointestinal stromal tumors.Semantic proximity Read ↗

Integrated Molecular Characterization of Gastrointestinal Stromal Tumors (GIST) Harboring the Rare D842V Mutation in PDGFRA GeneSemantic proximity Read ↗

Neomorphic PDGFRA extracellular domain driver mutations are resistant to PDGFRA targeted therapiesSemantic proximity Read ↗

KRAS and KIT Gatekeeper Mutations Confer Polyclonal Primary Imatinib Resistance in GI Stromal Tumors: Relevance of Concomitant Phosphatidylinositol 3-Kinase/AKT Dysregulation.Semantic proximity Read ↗

Acquired resistance to imatinib in gastrointestinal stromal tumours caused by multiple KIT mutations.Semantic proximity Read ↗

PDGFRA mutations in gastrointestinal stromal tumors: frequency, spectrum and in vitro sensitivity to imatinib.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.